Sam Aksah
Research Subjects
Sam Aksah has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Abraham Sunil
Department of Animal Behavior and Physiology, Madurai Kamaraj University, Madurai, India
1 shared publication - Konda Mani Saravanan
Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, India
1 shared publication - Meera Prabhakar
Bacteriology Group, ICMR-National Institute of Virology, Pune 411021, India
1 shared publication - Muthu Kannan
Department of Bioinformatics, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India
1 shared publication - Nagaraj Bharathkumar
B Aatral Biosciences Private Limited, Bangalore, India
1 shared publication - Thirunavukarasou Anand
Department of Cell Biology & Molecular Genetics, Sri Devaraj Urs Academy of Higher Education and Research (Deemed to be University), Kolar, Karnataka, 563103, India
1 shared publication
Latest Publications
- 6 November 2021
- Published by Springer Nature in Molecular Biotechnology
- Vol. 64 (4) , 355-372
CRISPR/Cas-Based Modifications for Therapeutic Applications: A Review
The CRISPR–Cas genome editing system is an intrinsic property of a bacteria-based immune system. This employs a guide RNA to detect and cleave the PAM-associated target DNA or RNA in subsequent infections, by the invasion of a similar bacteriophage. The discovery of Cas systems has paved the way to overcome the limitations of existing genome editing tools. In this review, we focus on Cas proteins that are available for gene modifications among which Cas9, Cas12a, and Cas13 have been widely used in the areas of medicine, research, and diagnostics. Since CRISPR has been already proven for its potential research applications, the next milestone for CRISPR will be proving its efficacy and safety. In this connection, we systematically review recent advances in exploring multiple variants of Cas proteins and their modifications for therapeutic applications.
- 6 November 2021
- Published by Springer Nature in Molecular Biotechnology
- Vol. 64 (4) , 355-372
CRISPR/Cas-Based Modifications for Therapeutic Applications: A Review
The CRISPR–Cas genome editing system is an intrinsic property of a bacteria-based immune system. This employs a guide RNA to detect and cleave the PAM-associated target DNA or RNA in subsequent infections, by the invasion of a similar bacteriophage. The discovery of Cas systems has paved the way to overcome the limitations of existing genome editing tools. In this review, we focus on Cas proteins that are available for gene modifications among which Cas9, Cas12a, and Cas13 have been widely used in the areas of medicine, research, and diagnostics. Since CRISPR has been already proven for its potential research applications, the next milestone for CRISPR will be proving its efficacy and safety. In this connection, we systematically review recent advances in exploring multiple variants of Cas proteins and their modifications for therapeutic applications.